EU approves Amgen’s UPLIZNA, first CD19 therapy for antibody‑positive generalized myasthenia gravis

EU authorisation expands Amgen’s neuromuscular portfolio

Amgen wins European Commission approval for UPLIZNA (inebilizumab) as an add‑on to standard therapy for adults with generalized myasthenia gravis (gMG) who are seropositive for acetylcholine receptor (AChR) or muscle‑specific kinase (MuSK) antibodies. The decision marks the first CD19‑directed therapy authorised in Europe for these patient groups and comes after regulatory review of phase 3 data from the Myasthenia Gravis Inebilizumab Trial (MINT).

First‑in‑class CD19 therapy cleared for antibody‑positive gMG

The EC approval is based on MINT, the largest biologic phase 3 study to include both AChR‑ and MuSK‑positive patients and the first to include a structured steroid‑reduction protocol. UPLIZNA is administered as two initial doses followed by a maintenance dose twice a year. Regulators note durable disease control and a regimen that may reduce the need for long‑term steroids in appropriate cases.

MINT implements a predefined steroid taper beginning at week four with a target prednisone dose of 5 mg/day by week 24. By week 26, 87.4% of patients receiving UPLIZNA and 84.6% of those on placebo have reduced steroids to 5 mg/day or less under the trial’s protocol. Amgen highlights selective depletion of CD19‑expressing B cells as addressing a core pathogenic mechanism in this B‑cell–dependent autoimmune disorder and says the biannual maintenance schedule supports convenience and potential long‑term disease control.

Company and clinician perspectives, next steps

Amgen frames the approval as expanding treatment options and plans to work with European health systems on reimbursement and timely access for eligible adults. Cesar Sanz Rodriguez, head of medical affairs at Amgen, emphasises the potential for reduced steroid exposure with twice‑yearly dosing, while clinical experts cite CD19 targeting as a meaningful mechanistic advance for a complex, rare condition.

Patient impact and access considerations

gMG is a rare, unpredictable disease estimated to affect between 56,000 and 123,000 people in Europe. Access will depend on national reimbursement decisions and uptake by neurologists, with Amgen indicating it will pursue payer discussions to facilitate patient access across member states.

Industry backdrop and strategic implications

The approval arrives as major European drugmakers prepare for a wave of patent expiries and focus on pipeline replenishment and targeted acquisitions. Analysts say 2026 is shaping up as a pivotal year for launches, pricing rules and M&A that will influence how companies like Amgen translate regulatory wins into sustainable growth.